<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Every day a drug sits in development is a day someone doesn't get better. In biotech's AI-powered future, velocity has become as fundamental as funding.">
    <title>When Speed Is Everything - Velocity Foundry</title>
    <link rel="stylesheet" href="../assets/css/style.css">
    <link rel="stylesheet" href="../assets/css/animations.css">
    <link rel="stylesheet" href="../assets/css/blog.css">
</head>
<body>
    <!-- Navigation -->
    <nav class="nav">
        <div class="container">
            <a href="../index.html" class="nav-logo">Velocity Foundry</a>
            <ul class="nav-menu">
                <li><a href="../assess.html">Assess</a></li>
                <li><a href="../tools.html">Tools</a></li>
                <li><a href="../book.html">Book</a></li>
                <li><a href="../blog.html">Blog</a></li>
            </ul>
        </div>
    </nav>

    <!-- Post Hero -->
    <section class="post-hero" style="background-image: url('../assets/images/congestion.png');">
        <div class="post-hero-content">
            <time>September 2, 2024</time>
            <h1>When Speed Is Everything</h1>
            <p class="post-byline">By Johan Strömquist</p>
        </div>
    </section>

    <!-- Post Content -->
    <article class="container" style="padding: 0 var(--space-md) var(--space-xl);">
        <nav class="post-nav" style="border-bottom: 2px solid var(--gray-200); padding-bottom: var(--space-sm); margin-bottom: var(--space-lg);">
            <a href="../blog.html">← All Posts</a>
        </nav>

        <div class="post-content">
            <p>Every day a drug sits in development is a day someone doesn't get better. A day a family waits. A day a disease wins.</p>

            <p>This has always been biotech's uncomfortable truth - that our careful, methodical pace comes at a human cost. We've consoled ourselves that this is the price of safety, the necessary trade-off for getting it right. That moving faster would mean moving recklessly.</p>

            <p>What if that's no longer true?</p>

            <p>What if the old equation - speed versus safety, velocity versus quality - is obsolete? What if the opposite is becoming true: that in biotech's AI-powered future, companies primarily die from not moving fast enough?</p>

            <h2>The Great Inversion</h2>

            <p>Something fundamental has shifted in our industry. AI is changing the relationship between speed and quality.</p>

            <p>Quality assurance? Increasingly automated, with AI systems that catch errors humans miss. Regulatory compliance? AI can now generate submission documents in minutes, not months, while ensuring every claim is backed by data. Creative molecule design? Algorithms are inventing novel drug candidates with optimal properties, collapsing years of trial-and-error into months.</p>

            <p>Insilico Medicine reached human trials with an AI-designed drug in just 30 months - versus the typical 6 years. Pfizer and Moderna went from genetic sequence to mass-produced COVID vaccine in under a year. These aren't anomalies. They're glimpses of the new normal.</p>

            <p>These capabilities aren't replacing the need for quality, safety, and compliance - they're making them faster and more reliable to achieve. When the basics become automated baselines, what distinguishes one biotech from another?</p>

            <p>Increasingly, just one thing: velocity.</p>

            <h2>The Compound Effect</h2>

            <p>One thing most people miss about speed, is that it compounds.</p>

            <p>A company moving 5x faster doesn't just reach market first. It runs 5x more experiments. It learns from 5x more failures. It iterates through 5x more hypotheses. Each acceleration multiplies the next - faster discovery enables faster trials, which enables faster manufacturing scale-up, which enables faster market feedback, which enables faster next-generation development.</p>

            <p>Consider clinical trials, traditionally the slowest phase. AI now optimizes trial design, identifies patients in days instead of months, and monitors results in real-time. TriNetX's AI-driven recruitment solution boosted enrollment conversion from 33% to 85% in Crohn's disease trials by using machine learning to identify and prioritize high-risk patients. Trials that dragged for years can now complete in months.</p>

            <p>But the company that finishes trials faster doesn't just save time - it frees resources to run more trials, test more indications, explore more combinations.</p>

            <p>Speed begets speed. Velocity compounds. The fast get faster.</p>

            <h2>Death of Digital Friction</h2>

            <p>The traditional biotech IT landscape is a graveyard of multi-year implementations, rigid systems, and "that's how we've always done it." Nearly half of life science companies still rely on spreadsheets for critical operations. Legacy software deployments take months or years.</p>

            <p>Enter the age of "fast fashion software."</p>

            <p>With AI pair-programmers and no-code platforms, a biotech can now spin up custom tools in days. Need a bespoke lab information system? An AI assistant can generate it over a weekend. Want to prototype a new clinical data workflow? Drag, drop, deploy.</p>

            <p>Your digital infrastructure should evolve as fast as your science. When tools can be rebuilt, reconfigured, or discarded as quickly as your hypotheses change, friction disappears. The organization becomes liquid, flowing around obstacles instead of crashing into them.</p>

            <p>Your tech stack should have the shelf life of a hypothesis - useful until it isn't, then rapidly replaced with something better.</p>

            <h2>The New Darwinian Game</h2>

            <p>This is becoming a matter of organizational survival.</p>

            <p>The gap between fast and slow biotechs compounds over time. While a traditional biotech spends 12-15 years bringing a drug to market, an AI-native competitor might do it in 5-7. They're not just years ahead - they've had multiple learning cycles the slower company hasn't even started.</p>

            <p>In five years, the distance between AI-native biotechs and traditional ones won't be measured in time. It'll be measured in capabilities, knowledge, and market position that can't be caught up to.</p>

            <p>Velocity is becoming as fundamental as funding.</p>

            <h2>The Cultural Revolution</h2>

            <p>Most biotechs are culturally wired for slowness.</p>

            <p>Academic founders bring a "publish when perfect" mentality. Big Pharma veterans import layers of review. Risk-averse boards demand exhaustive analysis before every move. This careful culture made sense when speed meant cutting corners.</p>

            <p>But when AI helps ensure quality at velocity, this culture becomes a constraint. You need disciplined urgency - the rigor of enterprise with the metabolism of a startup.</p>

            <p>This means:</p>

            <ul>
                <li>Default to action when AI has de-risked the decision</li>
                <li>Question every approval layer that doesn't add unique human judgment</li>
                <li>Treat time as your scarcest resource, not capital</li>
            </ul>

            <p>The question isn't "How can we move faster?" It's "What's actually requiring us to move slowly?" Every layer of approval, every committee meeting, every "let's study this further" is now a choice to delay helping patients.</p>

            <h2>The Velocity Playbook</h2>

            <p>So how do you actually build a velocity-first biotech? Start here:</p>

            <h3>1. Invest in organizational digital capabilities - beyond ChatGPT licenses</h3>

            <p>Build internal AI literacy. Train your team to use AI as creative partners, not just search engines. Create pools of "citizen developers" who can spin up quick tools without waiting for IT.</p>

            <h3>2. Audit every process through one lens</h3>

            <p>For each workflow, meeting, approval step ask: "Is human judgment adding unique value here?" If not, automate it. Better yet, eliminate it entirely. Most processes exist because they always have, not because they must.</p>

            <h3>3. Partner for acceleration</h3>

            <p>Find vendors and partners who share your velocity mindset. If they talk about "careful phase-gates" and "traditional timelines," run. The entire ecosystem around you should be pulling you forward, not holding you back.</p>

            <h3>4. Measure velocity religiously</h3>

            <p>Track cycle times for everything - from experiment design to data analysis to decision-making. Make these metrics visible. Celebrate speed improvements like you celebrate scientific breakthroughs.</p>

            <h3>5. Create "speed infrastructure"</h3>

            <p>Establish rapid decision-making forums. Set up automated data pipelines. Build templates for common workflows. Make going fast the path of least resistance.</p>

            <p>This isn't about being reckless. It's about removing the friction between idea and execution, between data and decision, between discovery and delivery.</p>

            <h2>Velocity as North Star</h2>

            <p>Forget balanced scorecards. Abandon complex KPI frameworks. In the age of AI-assured quality, you need only one metric: velocity.</p>

            <p>Judge every decision through a single lens: "Does this make us faster?"</p>

            <ul>
                <li>Hiring? Hire for speed of decision-making.</li>
                <li>Partnerships? Partner with those who can keep pace.</li>
                <li>Technology? Implement only what accelerates.</li>
                <li>Process? Eliminate anything that doesn't directly drive velocity.</li>
            </ul>

            <p>When velocity becomes your north star, something unexpected happens. The organization develops a metabolic rate that matches the pace of scientific discovery itself. Decisions that once took weeks happen in days. Experiments that queued for months run in parallel. The entire company begins operating at the speed of insight rather than the speed of bureaucracy. This is what velocity as an organizing principle actually delivers: an organization that moves as fast as the science allows, not as slow as the process demands.</p>

            <h2>The Moral Reckoning</h2>

            <p>Let's return to where we started - with patients waiting.</p>

            <p>In a world where AI can design molecules in months instead of years, where clinical trials can be optimized to cut timeline in half, where manufacturing can scale in weeks instead of months, what excuse remains for moving slowly?</p>

            <p>The old trade-off is dead. Speed and safety are no longer opposites - they're aligned. Moving fast doesn't mean moving recklessly. It means fulfilling our fundamental promise to patients: that we'll bring them help as quickly as humanly possible.</p>

            <p>And "humanly possible" has just been radically redefined.</p>

            <p>If you can move faster - if AI has removed the barriers, eliminated the friction, automated the safeguards - and you choose not to, that's no longer prudence. That's a choice. A choice that costs lives.</p>

            <p>The future belongs to biotechs that embrace velocity as their core organizing principle. Not at the expense of quality or safety - those remain non-negotiable - but as the natural outcome of doing those things smarter.</p>

            <p>In the race against disease, speed has always mattered. Now, for the first time, we can have both speed and safety. The question isn't whether you'll adapt to this new reality. It's whether you'll adapt fast enough to survive it.</p>

            <p>The age of choosing between fast and careful is over. The age of being both has begun. If you're ready to explore what velocity-first biotech looks like for your organization, reach out to us at SSI Strategy. We help biotechs build the capabilities and culture to move at the speed of science.</p>
        </div>

        <nav class="post-nav">
            <a href="../blog.html">← Back to all posts</a>
        </nav>
    </article>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <div class="footer-content">
                <div class="footer-section">
                    <h4>About</h4>
                    <p>By Johan Strömquist, President & Chief Innovation Officer at SSI Strategy / NDA Group</p>
                </div>
                <div class="footer-section">
                    <h4>Contact</h4>
                    <p>Email: <a href="mailto:johan.stromquist@ssistrategy.com">johan.stromquist@ssistrategy.com</a></p>
                    <p>LinkedIn: <a href="https://linkedin.com/in/johanstromquist" target="_blank">@johanstromquist</a></p>
                </div>
                <div class="footer-section">
                    <h4>Resources</h4>
                    <ul>
                        <li><a href="../assess.html">Velocity Assessment</a></li>
                        <li><a href="../tools.html">Templates & Tools</a></li>
                        <li><a href="../book.html">The Book</a></li>
                        <li><a href="../blog.html">Blog</a></li>
                    </ul>
                </div>
            </div>
            <div class="footer-bottom">
                <p>&copy; 2025 Johan Strömquist. All rights reserved.</p>
                <p class="footer-motto">Transform faster. Deliver sooner. Live better.</p>
            </div>
        </div>
    </footer>
</body>
</html>